Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ned Tijdschr Geneeskd. 2008 Apr 12;152(15):876-9.

[New drugs; exenatide and sitagliptin].

[Article in Dutch]

Author information

  • 1Leids Universitair Medisch Centrum, Albinusdreef 2, 2333 ZA Leiden.

Abstract

Incretin hormones, secreted upon food intake, play an important role in the regulation of blood glucose levels. In type 2 diabetes mellitus, the incretin response is decreased. Substitution of incretin is a novel pharmacological target which restores postprandial glucose homeostasis. Exenatide is a mimetic of the incretin glucagon-like peptide-I (GLP-I). Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4 (DPP-4), which breaks down GLP-I. Both drugs increase the GLP-I concentration, thereby improving insulin secretion from pancreatic p cells, restoring glycaemic control, preventing beta cell destruction, delaying gastric emptying, and reducing food intake.

Comment in

PMID:
18512528
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk